Peptides are getting the DIY treatment. Doctors are concerned.

Longevity doctors say DIY peptide injections are rising, and they're seeing cases of allergic reactions, hormone disturbances ...
GEN - Genetic Engineering and Biotechnology News

Regenerative Medicine: Promise, Hype, and What Actually Works

Therapies like PRP and ACS have gained credibility when properly applied and studied, particularly in musculoskeletal conditions.
Medscape

Lonapegsomatropin Shows Long-Term Benefit in Adult GHD

A 52-week extension study showed that the drug continues to maintain favorable body composition with no safety issues.
Endocrinology Advisor

Lonapegsomatropin Safety, Efficacy Sustained Through 90 Weeks

Once-weekly lonapegsomatropin shows sustained safety and efficacy up to 90 weeks in adults with GHD, according to AACE 2026 ...
Live Science

A single injection of mRNA-like treatment healed heart muscle after a heart attack in mice and pigs. Could it work in humans too?

Researchers boosted levels of a heart-healing hormone in mice and pigs with a single injection of a new, experimental form of self-amplifying RNA that prolonged hormone synthesis for many weeks. When ...
Reuters

Ghana to submit UN resolution on slavery reparations; eyes broad support

LONDON, March 12 (Reuters) - Ghana intends to propose a United Nations resolution recognising transatlantic slavery as ‌the "gravest crime in the history of humankind" and calling for reparations, and ...
MarketWatch

FDA approves Novo Nordisk's Sogroya(R) as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

"Families and healthcare professionals now have the option to consider a once-weekly growth hormone as treatment with 313 injection free days per year for their children 2.5 years and older with ISS, ...
WBOC

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

PLAINSBORO, N.J., Feb. 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved three new indications for once-weekly Sogroya ® ...
Healio

FDA approves three new pediatric indications for once-weekly growth hormone injection

Please provide your email address to receive an email when new articles are posted on . Somapacitan-beco is a once-weekly growth hormone injection. New indications expand treatment options for ...
journalgazette

FDA approves Novo Nordisk's Sogroya® as the first and only once-weekly, long-acting growth hormone for three additional pediatric indications

New indications expand treatment options for appropriate children aged 2.5 years and older with Idiopathic Short Stature (ISS), born Small for Gestational Age (SGA), or Noonan Syndrome (NS) 1 Sogroya ...
AOL

This “Natural” Injection Promises Pain Relief, Hair Growth, and More. But Does It Work And Is It Safe?

EVERY DAY FOR nearly 15 years, Raynie Canoy woke up in head-to-toe pain that made it hard to function. Her neck, back, and knees ached, and her hips felt so tight that some days she could barely bend ...
Popular Mechanics

This Breakthrough Injectable Can Reprogram Your Cells—To Regrow Parts of Your Body

The squishy insoles in your favorite pair of sneakers help keep your joints safe from daily wear-and-tear, but over time, that cushioning wears down. The same goes for your cartilage—the fibrous ...